Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
Status:
Active, not recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
Cigarette smoking is the leading preventable cause of premature death worldwide. However
smoking is a very difficult addiction to break whereby main reasons for not quitting or
relapsing after cessation are the nicotine withdrawal syndrome and post-cessational weight
gain. GLP-1 analogues are well known to stimulate insulin secretion and to reduce energy
intake and therefore body weight. Recent findings from animal and human studies suggest a
role of GLP-1 in the pathophysiology of addiction. The putative role of GLP-1 analogues in
nicotine reward regulation combined with its weight reducing effects might be of major
interest in view of novel pharmacotherapeutic options for smoking cessation.